Brevital® Sodium is administered via:
Facilities for assisting ventilation and administering oxygen are necessary adjuncts for all routes of administration of anesthesia. Since cardiorespiratory arrest may occur, patients should be observed carefully during and after use of Brevital® Sodium. Age- and size-appropriate resuscitative equipment (i.e., intubation and cardioversion equipment, oxygen, suction, and a secure intravenous line) and personnel qualified in its use must be immediately available.
Preanesthetic medication is generally advisable. Brevital® Sodium may be used with any of the recognized preanesthetic medications.
Preparation of Solution—FOLLOW DILUTING INSTRUCTIONS EXACTLY. Solutions of Brevital® Sodium should be freshly prepared and used promptly. Reconstituted solutions of Brevital® Sodium are chemically stable at room temperature for 24 hours.
Diluents—DO NOT USE DILUENTS CONTAINING BACTERIOSTATS.
Preferred Diluent: Sterile Water for Injection.
Acceptable Diluents: 5% Dextrose Injection (for IV or rectal administration only), 0.9% Sodium Chloride Injection.
Incompatible Diluents: Lactated Ringer’s Injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
WARNING
Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See WARNINGS)
